Literature DB >> 29920137

Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor.

Nemer El Mouallem1, Steven C Smith1, Asit K Paul1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29920137     DOI: 10.1200/JOP.18.00213

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  3 in total

1.  A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.

Authors:  Inkeun Park; Hyo Jin Lee; Woo Kyoon Bae; Shinkyo Yoon; Jae Lyun Lee
Journal:  Invest New Drugs       Date:  2019-06-24       Impact factor: 3.850

2.  The Role of Cytoreductive Nephrectomy and Targeted Therapy on Outcomes of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Population-Based Analysis.

Authors:  Taha Al-Juhaishi; Xiaoyan Deng; Dipankar Bandyopadhyay; Asit Paul
Journal:  Cureus       Date:  2022-05-27

Review 3.  Sarcomatoid renal cell carcinoma: biology, natural history and management.

Authors:  Jose A Karam; A Ari Hakimi; Kyle A Blum; Sounak Gupta; Satish K Tickoo; Timothy A Chan; Paul Russo; Robert J Motzer
Journal:  Nat Rev Urol       Date:  2020-10-13       Impact factor: 14.432

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.